Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
60-Word AI Digest
Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again. Reporting by CNBC highlights major developments in this space as key stakeholders evaluate broader implications. Further data and contextual analysis are actively being published. Access the full coverage dispatch below for complete documentation.
Key Takeaways
- Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
- Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
- Click full coverage link below for the complete official dispatch.
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Original Publisher Attribution
This summary was curated from CNBC.